News

Resonance Health is pleased to announce the introduction of a new product to customers in Australia, New Zealand and Europe with the launch of a FerriScan and cardiac T2* dual analysis service.

Patients with high liver iron content are at a greater risk of future cardiac complications and premature death. FerriScan accurately measures liver iron concentration, which generally precedes changes in heart iron loading, acting as an early warning of possible future cardiac complications.

Iron-induced damage to heart tissue can be halted and reversed if appropriate chelation therapy is commenced in time. Measurement of cardiac T2* with MRI enables assessment of the risk of iron-induced arrhythmia and cardiac failure. Regular and accurate FerriScan liver iron concentration and cardiac T2* measurements enable better informed decisions on the management of patients at risk of iron overload.

MRI centres equipped with suitable scanners are able to send both cardiac and liver images to the Resonance Health ISO – accredited service facility for analysis. Reports on both liver iron concentration and cardiac T2* measurement will be available for download within a target time of 48 hours.

The official launch of the FerriScan and cardiac T2* dual analysis service is taking place at the 2nd Pan-European Conference on Haemoglobinopathies in Berlin on 13 – 14 March 2010.

Click here to request further information on this service.